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Introduction: Systemic lupus erythematosus (SLE) is a chronic inflammatory condition with multisystem
involvement. One of the key features of the disease is the upregulation of type I interferons, resulting in the
so-called “interferon signature”. Recent flow cytometric and transcriptomic studies identified Sialoadhesin
(Sn, CD169) as an important interferon-induced blood monocyte biomarker in diseased patients. To investigate a
potential causative role of Sn in SLE, we generated NZBWF1 (New Zealand Black x New Zealand White F1) mice
lacking Sn and compared onset and progression of disease with NZBWF1 expressing normal levels of Sn.
Methods: Sn expression in renal tissues of pre-diseased and diseased NZBWF1 mice was evaluated by Quantitative
real time PCR (QPCR) and immunohistochemistry. Sn−/− NZBWF1 mice were generated by speed congenics. Disease
severity of Sn+/+ and Sn−/− NZBWF1 mice was assessed by serum immunoassays, flow cytometry, light microscopy
and immunohistochemistry.
Results: Renal tissues from proteinuric NZBWF1 mice exhibited a significant upregulation of Sn mRNA and protein
expression following disease onset. Further immunohistochemical analysis showed that Sn+ macrophages assumed
a distinct periglomerular distribution and, unlike CD68+ macrophages, were not present within the glomeruli.
Analysis of disease severity in Sn−/− and Sn+/+ NZBWF1 mice revealed no significant differences in the disease
progression between the two groups although Sn-deficient mice showed a more rapid onset of proteinuria.
Conclusions: These data confirm a positive correlation of Sn with disease activity. However, Sn deficiency does not
have a significant effect on the severity and progression of lupus nephritis in the NZBWF1 mouse model.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
chronic inflammatory condition with a multi-system pat-
tern of involvement. SLE is the prototype of systemic
autoimmunity of unknown aetiology [1]. The disease is
characterized by loss of self-tolerance and accelerated
apoptosis with subsequent release of nucleosomal mate-
rial, which is a major target for immune responses [2].
Failure to clear these apoptotic materials results in
expansion of autoreactive lymphocytes, with increased
formation of autoantibody [3,4]. Increased levels of
antigen-antibody immune-complexes lead to deposition* Correspondence: p.r.crocker@dundee.ac.uk
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reproduction in any medium, provided the orof these in various tissues, causing inflammation and
damage by activation of other immune pathways, for
example, the complement system. The kidneys are prime
sites for immune complex deposition, resulting in glo-
merulonephritis [5]. Type I IFNs, particularly IFNα, were
found to be markedly upregulated in patients with active
SLE [6]. Interestingly, there was a tendency in the
high-IFN group to develop renal, haematological and
central nervous system (CNS) disease. These findings
confirmed a correlation between this interferon signa-
ture and disease severity.
Sialoadhesin, (Sn, CD169, siglec-1) is the prototype of
sialic acid-binding immunoglobulin-like lectins (Siglecs)
[7]. Sn is a macrophage-restricted adhesion molecule
that is expressed on macrophages of the marginal meta-
lophilic zone and subcapsular sinus in spleen and lymph
nodes respectively. Sn expression can be induced onLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cially under the influence of IFNα [8-11]. Consistent with
this observation, Sn was identified as a biomarker for the
type I IFN-signature in SLE [12,13]. The expression of Sn
on blood monocytes was found to correlate with disease
severity and other established biomarkers of the disease.
However, the role of Sn in this complex polygenic disease
is not clear. The correlation between Sn expression and
disease severity suggested a pro-inflammatory role for the
molecule. In support of this hypothesis, Sn deficiency was
found to ameliorate disease severity in other mouse
models of autoimmunity [14-17]. Alternatively, Sn expres-
sion might reflect disease activity without a direct role in
the disease pathogenesis. The evidence for either argu-
ment in SLE is lacking.
These findings prompted us to examine the potential
role of Sn in a well-established murine model of SLE,
New Zealand black X New Zealand white F1 (NZBWF1)
mice. In this study we examined the expression of Sn in
renal cortical tissues prior to disease onset and in diseased
mice. We found that the frequency of Sn+ macrophages
directly correlated with histological severity. To determine
the impact of Sn in disease pathogenesis, we generated
Sn-deficient (Sn−/−) NZBWF1 mice using a speed con-
genics approach. Surprisingly, there was no significant dif-
ference in disease severity between wild-type (WT) and
Sn-deficient mice. These findings indicate that Sn repre-
sents a biomarker for the disease rather than contributing
a dominant role in the pathogenesis.
Methods
Mice
New Zealand white (NZW), New Zealand black (NZB)
and NZBWF1 mice were purchased from Harlan Labora-
tories (Oxford, UK) or bred and maintained by Biological
Services at the University of Dundee, (Dundee, UK). The
generation of Sn-deficient mice was previously reported
by our laboratory [18]. The Sn-deficient mice that were
initially used to generate Sn−/− NZBWF1 mice were inter-
cross offspring of heterozygotes backcrossed for more
than 20 generations onto a C57BL/6 background. Mice
were housed under specific-pathogen-free conditions. The
animal protocols used in this study were approved by the
Ethical Review Committee of the University of Dundee.
All procedures involving living animals were conducted
according to the requirement of the United Kingdom
Home Office Animals Scientific procedures Act (1986),
under PPL60/3856.
Generation of Sn−/−NZBWF1 mice
The generation of NZBWF1 mice deficient for Sn was
done in three phases: (1) generation of parallel NZB and
NZW mice that are heterozygous for Sn; (2) crossing Sn
heterozygous mice for each strain to generate NZB andNZW mice wild-type and deficient for Sn; (3) inter-
crossing WT or Sn-deficient male NZW mice with WT
or Sn-deficient NZB mice, to generate Sn WT and Sn−/−
NZBWF1 mice.
Speed congenics [19] was employed to transfer a
set of predefined NZB and NZW susceptibility loci
(Additional file 1) to recipient mice that are heterozygous
for Sn. Monitoring the introgression of these loci was
examined by genotyping with microsatellite markers
(20 for NZB and 25 for NZW).
Ear biopsies from mice in each progeny were genotyped
initially for the presence of the Sn mutation. All Sn hete-
rozygous NZB and NZW male mice were then screened for
relevant polymorphic markers (Additional file 1). Once all
required susceptibility loci were introgressed, further geno-
typing was done for Sn only. All PCRs were done using the
GoTaq®Flexi DNA polymerase PCR kit (Promega, South-
amptom, UK) using 100 mM 2’-deoxynucleoside 5’-triphos-
phate (dNTP) purchased from Invitrogen. The primer sets
used in genotyping of NZW polymorphic markers were
designed using Primer Express software 2.0 (Applied Bio-
systems, California, USA), also found in Additional file 1.
Quantitative reverse transcription PCR (qRT-PCR)
RNA extraction was done using RNeasy mini kit (Qiagen,
Manchester, UK) according to manufacturer’s instructions.
In this protocol, renal cortical samples from the left kidney
were lysed in the presence of denaturing guanidine-
thiocyanate-containing buffer to inactivate RNases. Sample
homogenization was done with a rotor-stator homogenizer
using homogenization tubes containing 1.4-mm ceramic
beads (Precelys, Peqlab, Southampton, UK).
The concentration of the extracted RNA was measured
based on the absorbance at 260 nm (A260) in a NanoDrop
1000 spectrophotometer (Thermoscientific, Massachusetts,
Boston, USA). The purity of RNA was estimated by
measuring the ratio of the readings at 260 nm and 280 nm
(A260/A280). Sample ratios between 1.9 and 2.1 were
regarded as acceptable for cDNA preparation.
cDNA synthesis was performed using a QuantiTect re-
verse transcription kit (Qiagen). All incubations were done
in a thermocycler (Bio-Rad, Hertfordshire, UK) for the spe-
cified temperatures and durations. All cDNA samples were
stored at −20°C until used in qRT-PCR experiments. cDNA
was subsequently quantified with a StepOne Plus detection
system (Applied Biosystems, California, USA) using specific
primers for each marker and a SYBR Green-based detection
system (Applied Biosystems, California, USA). Input RNA
was normalised between samples using GAPDH as an en-
dogenous control. Fold upregulation of the target gene was
calculated as ratio target gene expression (experimental/
control). Primers used in these experiments were as follows:
SnD2 5’-CCCAGCCCCCCCACTAT-3’ and 5’-AAGTTCC
TCTCCATGCCTTCAC-3’; CD68 5’-CTTCCCACAGGCA
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G-3’; IFNαR1 5’-TGGTGGTTCTGTCTCGGTGTT-3’ and
5’-GCTACGGCAGGATTAAAAATCG-3’; IFNγ 5’-AGCT
CTTCCTCATGGCTGTT-3’ and 5’-TTTGCCAGTTCCT
CCAGATA-3’; IL-1β 5’-AAGTGATATTCTCCATGAGC
TTTG-3’ and 5’-TTCTTCTTTGGGTATTGCTTGG-3’.;
TNFα 5’-CGTCGTAGCAAACCACCAAG-3’ and 5’-TTG
AAGAGAACCTGGGAGTAGACA-3’; IL-6 5’-TGGGAAA
TCGTGGAAATGAG-3’ and 5’-CTCTGAAGGACTCTGG
CTTTG-3’.
Measurement of proteinuria
Mice were monitored for disease onset by testing urine with
a test strip (Uristix, Bayer, Berlin, Germany) for protein
excretion on a weekly basis until proteinuria was detected
and then thrice weekly thereafter. Results were graded ac-
cording to the extent of proteinuria as follows: 0 = negative
or trace, + = 30 mg/dl, ++ = 100 mg/dl, +++ = 300 mg/dl
and ++++ = >2,000 mg/dl. Onset of disease was defined as
two consecutive readings equal to or more than ++
(100 mg/dl).
Analysis of serum anti-ss/dsDNA
Sera from BWF1 mice were analysed for IgM and IgG anti-
ss/dsDNA titres using ELISA. Then, 96-well microtitre
plates were coated with 20 μg/ml of poly-L lysine (Sigma,
Dorset, UK) in deionised water overnight at 4°C. Plates were
washed three times with PBS and 20 μg/ml calf thymus
DNA was added for 3 hours at 37°C. Plates were washed
three times with PBS + 0.05% Tween (PBST) and non-
specific binding was blocked using PBS + 3% BSA for 1 hour
at 37°C. Following three washes with PBST, serial dilutions
of sera were added in triplicate for 2 hours at 37°C. Sera di-
lutions were started at 1/100 to 1/6,400 in PBS + 0.5% BSA.
Plates were washed three times with PBS + 0.5% BSA. Sec-
ondary antibodies diluted in PBS + 0.5% BSA used for detec-
tion of immunoglobulin (Ig)M and IgG anti-ss/dsDNA
included alkaline phosphatase-conjugated goat anti-mouse
IgM (Sigma, Dorset, UK) or horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgG (Sigma, Dorset, UK). This
was followed by five washes with PBST. Plates were devel-
oped either with p-nitrophenyl phosphate substrate (Sigma,
Dorset, UK) for alkaline phsophatase-conjugated secondary
antibodies or TMB substrate (BD Bioscience, Oxford, UK)
for HRP-conjugated secondary antibodies. Plate readings
were analysed at 405 nm for the former and 450 nm for the
latter. Pooled sera from old female NZBWF1 mice were
used as a positive control in all experiments.
Flow cytometry
All staining and washes were carried out in ice-cold
fluorescence-activated cell sorting (FACS) buffer (PBS +
0.5% BSA+ 2 mM ethylenediaminetetraacetic acid (EDTA)
+ 0.05% w/v sodium azide) and tubes incubated on ice tominimise antibody internalisation. Non-specific binding was
limited by incubation with 0.25 μg of anti-CD16/CD32 (Fc
blocking antibody 2.4G2, eBioscience, San Diego, California,
USA) per 1 million cells in 25 μl for 15 minutes. Surface
labelling was carried out for 30 minutes with optimal con-
centrations of the relevant antibodies as decided by prior
antibody titrations. The antibodies used in this study include
rat anti-mouse; -CD4 PerCp-Cyanine5.5 (clone RM4-5,
eBioscience, San Diego, California, USA); -CD8a BD Horizon
V500 (clone 53–6.7, BD eBioscience, San Diego, California,
USA); -CD19 FITC (clone eBio1D3, eBioscience, San Diego,
California, USA); -B220 Alexa Fluor 700 (clone RA3-6B2,
eBioscience, San Diego, California, USA), and -CD69 BD
Horizon V450 (clone H1.2 F3, BD Biosciences). Cells were
washed twice with FACS buffer followed by fixation and per-
meabilisation using the Foxp3/Transcription Factor Staining
Buffer Set (eBioscience, San Diego, California, USA) accord-
ing to the manufacturer’s instructions. Briefly, cells were
stained with rat anti-mouse Foxp3 Alexa Fluor 700 (clone
FJK-16, eBioscience, San Diego, California, USA) in perme-
abilisation buffer, washed twice in the same buffer and resus-
pended in FACS buffer. Samples were then analysed with a
BD LSR Fortessa (BDBiosciences, University of Dundee,
Central Services) followed by FlowJo version 7.6.4.
Renal histology and assessment of disease severity
The right kidney was used for assessing lupus nephritis
severity by light microscopy. Kidneys were fixed in
10% neutral-buffered formalin. Processing and staining of
kidney sections was conducted by the Veterinary Services,
University of Glasgow, UK. Kidney sections (5 μm) were
stained with H&E or Masson’s trichrome and evaluated by
light microscopy. Scoring of nephritis severity included
examining glomeruli, tubular and perivascular regions, as
described previously [20]. Glomerular pathology was
assessed by counting the number of cells per glomerular
cross-section (gcs), of 30 glomeruli per kidney. The scoring
system was as follows; score 0, normal cellularity (35 to 40
cells/gcs); 1, mild hypercellularity (41 to 50 cells/gcs); 2,
moderate hypercellularity (51 to 60 cells/gcs) with segmen-
tal or diffuse proliferative changes; 3, severe hypercellularity
(>60 cells/gcs) with segmental or global sclerosis, crescent
formation and severe exudation. Tubular pathology was
assessed based on the percentage of tubules showing dilata-
tion or atrophy among 200 tubules in a randomly chosen
field. Perivascular cell accumulation was also evaluated by
counting the number of cell layers surrounding randomly
chosen inter- and intralobular arteries. Perivascular scoring
included; 0, no perivascular infiltrate; 1, less than 5 layers
surrounding less than half the diameter of the artery; 2, 5 to
10 layers surrounding more than half of the diameter of the
vessel; 3, more than 10 layers surrounding more than half
the diameter of the artery). Scoring of all kidney sections
was done in a blinded fashion.
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Kidneys were snap-frozen and stored at −80°C until sec-
tioned: 5-μM cryostat sections were prepared, air-dried
and fixed in acetone for 10 minutes. Rat anti-mouse
monoclonal antibodies against Sn (clone SER4 and 3D6,
in-house), CD68 (clone FA-11, eBioscience, San Diego,
California, USA), CD4 (clone L3T4, eBioscience, San
Diego, California, USA) and Foxp3 (clone FJK-16,
eBioscience, San Diego, California, USA) were used to as-
sess the presence of different cell populations. HRP-
labelled goat anti-rat Ig was used as secondary antibody
(mouse-adsorbed; Vector laboratories, Peterborough, UK).
Spleen tissues from Sn wild-type and deficient mice were
used as positive and negative controls for Sn, respectively.Sn CD6A
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Statistical significance was determined by the Mann–
Whitney test. A P-value was considered significant when
less than 0.05.Results
Sn expression is upregulated in renal tissue of diseased
NZBWF1 mice
Recent analyses of Sn+ monocytes in patients with active
SLE showed an increase in their frequency that matched
disease activity [12,13]. However, it is unclear whether Sn
expression is upregulated on macrophages in diseased
renal tissues. To this end, we examined the expression of8 F4/80
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in renal tissues of 28 week old proteinuric NZBWF1, age
matched NZW and pre-disease NZBWF1 mice by qRT-
PCR. This revealed that dramatic upregulation in the
mRNA expression of Sn, CD68 and F4/80 occurs in pro-
teinuric NZBWF1 mice (Figure 1A). There were no sig-
nificant differences between pre-disease NZBWF1 and
control NZW mice (data not shown). In order to confirm
the expression of Sn at a protein level, we used immuno-
histochemical staining for Sn and CD68 in renal tissues
from NZBWF1 mice. Consistent with the qRT-PCR ana-
lysis, Sn was absent in pre-diseased kidneys and increased
in renal tissues of diseased NZBWF1 mice (Figure 1B and
C). Interestingly, Sn+ macrophages assumed a distinct
periglomerular and tubulointerstitial distribution and, in
contrast to CD68+ macrophages, were not found within
the glomerular capillaries (Figure 1B).
Concomitant with upregulation of Sn in diseased
renal tissues of NZBWF1 mice, we also observed in-
creased expression of the Ifnar1 gene (Figure 2A),
similar to what has been reported previously in lupus-
prone MRL/lpr mice as part of the interferon sig-
nature [21]. In addition, genes encoding several pro-
inflammatory cytokines were found to be upregulated
in their expression, including IFNγ, TNFα, IL-1β and
IL-6 (Figure 2). Taken together, these data show that
Sn is upregulated in kidney tissues from nephriticIFNα1R
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Figure 2 Upregulation of inflammatory markers in renal tissues from
mice. (A-E) Gene expression in kidneys of NZBWF1 mice relative to New Z
markers by qRT-PCR using five mice per group. Statistical analysis was doneNZBWF1 mice and this is associated with enhanced
expression of a number of inflammatory cytokines.
Sialoadhesin deficiency does not affect the severity of
lupus nephritis in NZBWF1 mice
To investigate whether the strong upregulation of Sn is
important in the pathogenesis of lupus nephritis, we
generated Sn-deficient NZBWF1 mice as described in
Methods. Sn deficiency was confirmed by means of PCR
(data not shown) and immunohistochemistry of spleen
and kidney sections (Figure 3). Age-matched Sn+/+,
Sn+/− and Sn−/− mice were monitored for disease onset
(proteinuria) and progression leading to death (Figure 4A).
No significant differences were observed. However, 3
Sn−/− mice showed early proteinuria at weeks 16, 17
and 21, which subsided and then reappeared at weeks
21, 25 and 31 respectively, progressing to death. A
fourth Sn-deficient mouse developed early proteinuria
at week 21 which progressed. The earliest onset of
proteinuria in Sn-expressing mice was at week 23
and in all cases, disease was progressive (Figure 4A).
This difference in the early onset of proteinuria
between Sn-deficient mice and Sn-expressing mice
was significant (Fishers exact test, P = 0.04).
The analysis of serial serum samples from Sn+/+
and Sn−/− NZBF1 mice for IgM and IgG anti-dsDNA
showed no significant differences between the twoNZW
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Figure 3 Generation of sialoadhesin (Sn)-deficient NZBWF1 mice. Frozen sections from spleen (A) and kidney (B) of Sn+/+ and Sn−/− NZBWF1
mice were stained for Sn using immunohistochemistry.
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was also assessed histologically using the World
Health Organization (WHO) scoring system as
outlined in Methods. There were no significant
differences in glomerular, tubulointerstitial or18 18
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Figure 5 Flow cytometry of splenocytes from diseased sialoadhesin (Sn)+/+ and Sn−/− New Zealand black x New Zealand white F1
(NZBWF1) mice. (A-G) Splenocytes were isolated from 28-week-old diseased Sn+/+ (filled circles) and Sn−/− (open circles) NZBWF1 mice. Each
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CD4+ T cells
We have previously shown that Sn can interact with Sn
ligands (SnL) induced on a subset of highly activated,
potentially pathogenic CD4+Foxp3- effector T cells (Teffs)A
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we performed flow cytometric analysis (Figure 5). This
revealed a significant reduction in the percentage of CD4+
T cells in Sn−/− mice (Figure 5A), but there was no dif-
ference in CD8+ or CD19+B220+ cells (Figure 5B and C).
This reduction was observed in both Foxp3+ and Foxp3-
CD4+ subsets (Figure 5D and E). However, the per-
centages of CD4+Foxp3+ and CD4+Foxp3- T cells that
expressed the activation marker CD69 were both sig-
nificantly increased in spleens of Sn−/− mice (Figure 5F
and G). As activated CD4+ T cells express SnL [22], this is
consistent with a negative regulatory role of Sn on both
Teffs and Tregs in SLE.
In order to analyse the effect of Sn deficiency on CD4+
T cells in renal tissues of NZBWF1 mice, we examined the
frequency of CD4+ and Foxp3+ T cells using immunohis-
tochemistry. There were no differences in the frequency
of CD4+ T cells in glomeruli and tubulointerstitial tissues
between Sn+/+ and Sn−/− mice (Figure 6A and B). We were
unable to demonstrate positive Foxp3 staining in the
glomerular compartment, but the tubulointerstitial tissues
showed similar numbers of Foxp3+ cells in Sn+/+ and
Sn−/− mice (Figure 6C).
Discussion
The expression and function of Sn have been investigated
in a number of inflammatory conditions in animal models
and in humans [10,13-17,23-29]. The majority of these
studies suggested a pro-inflammatory role for the mole-
cule. Indeed, Sn deficiency in mice has been reported to
be associated with disease amelioration in several auto-
immune conditions [14-17]. Although increased Sn levels
were found to be representative of disease activity in
human SLE [12], it has remained unclear whether Sn plays
a direct role in the disease pathogenesis. In this study, we
found abundant Sn expression at the mRNA and protein
levels in the kidneys of nephritic mice. In addition, a num-
ber of cytokines that have been implicated previously in
the induction of Sn under inflammatory conditions were
also upregulated [30]. As there was a parallel increase in
gene expression of the pan macrophage markers CD68
and F4/80 in the nephritic mice, it is difficult to differen-
tiate between an enhanced induction of Sn on renal
macrophage subsets and generalised infiltration of kidney
tissues by macrophages. However, immunohistochemistry
analysis revealed that Sn+ macrophages were mainly dis-
tributed in a periglomerular manner and absent from the
glomerular tuft, unlike CD68+ macrophages. The signifi-
cance of this preferential anatomical location of Sn+ mac-
rophages is currently unclear.
Previously, Sn expression on macrophages in a model
of EAE was reported to downregulate numbers of
SnL+CD4+Foxp3+ Tregs via Sn-SnL interactions, leading
to increased disease severity [17]. Recently, we confirmedthe abundance of SnL on Tregs and also identified a
novel subset of activated CD4+Foxp3- Teffs bearing SnL
following TCR ligation in vitro [22]. A phenotypically
similar subset of SnL+CD4+Foxp3- Teffs was identified in
proteinuric NZBWF1 mice, with the frequency of this
subset correlating closely with disease status (proteinuria
presence versus absence) [22]. We therefore hypothe-
sized that Sn deficiency might be associated with an aug-
mented disease severity due to an increase in these
highly activated CD4+Foxp3- T cells. Surprisingly, how-
ever, despite an earlier onset of proteinuria, the disease
progression was not different between Sn+/+ and Sn−/−
mice. Since the frequency of both activated Teffs and
Tregs was enhanced in the spleens of Sn−/− mice, the net
outcome on CD4 T cell function could be neutral and
help explain why the severity of nephritis was similar re-
gardless of the genotype. Importantly, our results indi-
cate that unlike non-polygenic autoimmune conditions
studied previously [14-17], Sn deficiency does not affect
disease severity in SLE.
In conclusion, our findings suggest that Sn expression
is increased in murine lupus nephritis and correlates
with histological severity. However, Sn deficiency does
not affect the disease progression or histological severity.
Collectively, these data indicate that the role of Sn in
SLE is redundant. As demonstrated by others [12,13], Sn
serves as a potentially useful biomarker of inflammation
and disease severity in SLE.
Conclusions
In the NZBWF1 model of murine lupus nephritis, Sn
expression in the kidney was increased and correlated with
histological severity of disease. Although Sn deficiency was
associated with dynamic changes of splenic activated CD4 T
cells and earlier onset of disease, it did not affect disease pro-
gression or histological severity. Collectively, these data sug-
gest that Sn acts as a biomarker that is reflective of disease
in murine lupus nephritis rather than playing a causal role.
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markers used in generating BWF1 mice deficient for Sn.
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